Cystnil150 mg+550 mg

D-Chiro-Inositol + Myo-Inositol is indicated for the management of hormonal imbalance and insulin resistance–related reproductive disorders, especially in women with polycystic ovary syndrome (PCOS).

It is commonly used for:

• Polycystic Ovary Syndrome (PCOS) including menstrual irregularities, anovulation, acne, hirsutism, and weight-related metabolic issues
• Infertility due to ovulatory dysfunction and improved ovarian function
• Insulin resistance–related metabolic imbalance associated with PCOS
• Ovarian dysfunction and subfertility support
• Prevention of gestational metabolic complications such as gestational diabetes risk reduction
• Support in reproductive health optimization in women with hormonal imbalance

This combination helps improve insulin sensitivity, restore normal ovulation, and support overall reproductive and metabolic health.

D-Chiro-Inositol + Myo-Inositol are naturally occurring inositol isomers that play a key role in insulin signaling and ovarian function. This combination works synergistically to improve insulin sensitivity, regulate endocrine activity, and restore hormonal balance in women with polycystic ovary syndrome (PCOS).

Myo-inositol primarily supports follicular development and oocyte quality, while D-chiro-inositol contributes to improved insulin-mediated metabolic regulation. Together, they help normalize reproductive hormone levels, including reducing elevated luteinizing hormone (LH), testosterone, and prolactin, while restoring the balance between FSH and LH.

This combination enhances ovarian function by improving ovulation, egg quality, and menstrual regularity. It also reduces oxidative stress within ovarian follicles, supporting healthier reproductive outcomes.

Additionally, Cystnil 150 mg+550 mg improves insulin resistance, thereby reducing metabolic complications associated with PCOS and lowering the risk of gestational diabetes mellitus. Overall, this combination supports both reproductive and metabolic health, improving fertility outcomes in women with PCOS.

D-Chiro-Inositol + Myo-Inositol may interact with certain medications that affect cardiac function or blood glucose control.

With medicines:

• Digoxin: Concurrent use may increase the risk of digoxin toxicity, requiring careful monitoring of serum digoxin levels and clinical signs of toxicity.
• Antidiabetic drugs (e.g., insulin, metformin, sulfonylureas): May enhance blood glucose–lowering effects, increasing the risk of hypoglycemia. Dose adjustment and glucose monitoring may be necessary.

D-Chiro-Inositol + Myo-Inositol is generally well tolerated when used at recommended doses, with a low incidence of adverse effects.

Possible side effects include:

• Gastrointestinal discomfort: Nausea, mild diarrhea, or abdominal discomfort
• Flatulence (gas formation)

These side effects are usually mild, transient, and tend to resolve with continued use or dose adjustment.

If symptoms persist or become bothersome, medical advice should be sought.

D-Chiro-Inositol + Myo-Inositol has been evaluated in several human studies in pregnant women, showing no clinically relevant adverse effects when used at recommended doses.

Pregnancy:
Available clinical evidence suggests that this combination is generally safe during pregnancy and may help support insulin sensitivity and reduce the risk of gestational metabolic complications, including gestational diabetes. However, it should be used under medical supervision.

Lactation (Breastfeeding):
There are currently no sufficient published clinical data on the safety of D-Chiro-Inositol + Myo-Inositol during breastfeeding. Therefore, use during lactation should be based on a physician’s assessment of potential benefits versus risks.

General advice:
Use during pregnancy and lactation should always be guided by a healthcare professional to ensure safe and appropriate therapy.

D-Chiro-Inositol + Myo-Inositol should be used with caution in patients with underlying medical conditions due to limited clinical data in specific populations.

Key precautions include:

• Hepatic impairment: Limited data are available regarding use in patients with liver dysfunction. Patients with hepatic impairment should consult a physician before use.
• Medical supervision: Use should be guided by a healthcare professional, especially in patients with metabolic or endocrine disorders.
• Individual risk assessment: Patients with any chronic illness or concerns regarding liver health should undergo proper medical evaluation before starting therapy.

General warning:
Due to limited safety data in certain patient groups, D-Chiro-Inositol + Myo-Inositol should be used cautiously and only under appropriate medical supervision.

Store below 30° C temperature & dry place, protected from light. Keep all medicines out of reach of children.